|
THE
principal author of the House version of the cheaper
medicines bill on Thursday lamented what he described as
the “drastic weakening” of the measure with the removal
of the provision on the drug-price regulatory board
apart from the “generics- only” provision of the
original bill.
And
because of the latest development, Lakas Rep. Fernejel
Biron of Iloilo said he is not that optimistic that the
price of medicines will go down even if the bill were
passed into law.
Also,
Biron said he and other legislators who fought hard to
pass the bill are contemplating not signing the draft
report being prepared by the House panel for the
bicameral conference meeting on the measure.
“We are
considering not to sign [the final draft]. Pero
siyempre, hanggang Lunes pa ito baka may pagbabago pa sa
draft and baka mag-meet pa ulit pero sa
information na na-receive namin, hindi na
magmi-meet ang bicameral conference
committee, instead, you know papirmahan na lang sa
amin iyong final draft, which to me parang hindi
naman maganda,” Biron said following a news forum in
Quezon City on Thursday.
Biron
said that if the Senate contingent will force the
passage of a new version minus the generics-only
provision and the price regulatory board, which he
described as “the heart and soul” of the bill, the
Filipino people expects nothing from it because it is no
longer as effective as the original bill.
“Kung
talagang pilitin nila na ito ang bersyon na ipapasa, ah,
wala ng masyadong maasahan ung ating kababayan,”
Biron said.
“There
is a drastic weakening of the bill, nakikita natin na
apart from the fact na kinuha ang generic-only
provision, sana inasahan natin na iyong
drug-price regulatory board should have stayed because
that’s the most substantive and most important part of
the bill kasi inaasahan ng ating kababayan pag
ipinasa ang bill na ito, they would expect a
quantifiable reduction sa presyo ng mga gamot. Pero
sa ngayon wala na because ang board na
iyon inalis na rin and it was transferred to the
secretary of Health,” he added.
Biron
said that because of the weakening of the measure,
“cheaper medicine in the bill is just illusory.”
He said
that price regulation rests only on what has to be
regulated by the price regulatory board but what Sen.
Mar Roxas II wants is there should be prior
determination.
Lakas
Rep. Janette Garin, also of
Iloilo,
said in the same forum that what the Senate contingent
to the bicameral committee did to the House version was
such that “probably the title only, which is cheaper
medicine, remains.”
Garin
also lamented the “arrogance of the Senate. Kung ayaw
mo, di walang batas. Walang open-mindedness. Like
Cayetano [Sen. Pia Cayetano], may apprehension but
sinagot naming lahat iyon. But after we have
answered, hindi nila counter-acted ang mga ito,”
Garin said.
“Kung
walang board…come 2010 [election year] voters should
ask if talagang bumaba ang presyo ng gamot,” said
Garin, obviously alluding to the candidacy of Roxas for
president.
This was
echoed by Biron who said: “Alam ng tao na Senator
Roxas is the architect. It is for the Filipino people to
really see and determine whether what Roxas is pushing
is talagang bababa ang presyo ng gamot.”
The
draft bicameral conference committee report will soon be
routed for comments to House contingent members. The
timetable is to report it out for plenary vote next
week.
Kabalikat ng Malayang Pilipino Rep. Antonio Alvarez of
Palawan described the removal of the generics-only
provision as “a tactical retreat.”
“Faced
with an immoveable Senate, it is better to go home with
90 percent of a loaf of a bread than fight for the whole
loaf but ending up with none,” Alvarez said in a
statement.
Alvarez
said the House’s move to end the deadlock was,
however, not without conditions. “It is anchored on the
promise of the Senate that the generics-only provision
will be tackled in a separate bill that the Senate
health committee and the House health committee will
independently tackle and report,” Alvarez said.
He said
that it was the condition offered by the Senate, that in
exchange for the dropping of the generics-only
provision, the Senate Committee on Health will treat it,
together with other Generics Act-related measures, in a
separate legislation.
Malacañang, meanwhile, expressed confidence that the
cheaper-medicines bill would withstand legal scrutiny by
any group threatened by the impending availability of
affordable medicine in the country, as it has been duly
reviewed by lawmakers and would apply mostly to commonly
used medication with lapsed patents.
Press
Secretary Ignacio Bunye said in a news briefing that
many other countries have done the same but were not
confronted by legal questions, as warned by some
pharmaceutical companies.
“I
believe that all the legal grounds have been
covered...I’m confident that we have good legal ground
to stand on when we pass this law,” Bunye, a lawyer,
said.
He added
the Senate and the House of Representatives have enough
legal experts who have looked into the legal
implications of the bill, and found nothing unlawful
about it. (With M. Gonzalez) |